Trial · NCT07894874
A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors.
NCT07894874, Phase 1, Not yet recruiting, InventisBio Yiqi Beijing Limited
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors. Trials, record NCT07894874. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07894874
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors.
- NCT number
- NCT07894874
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 204 participants, estimated
- Lead sponsor
- InventisBio Yiqi Beijing Limited
- Conditions
- Solid Tumor (Phase I), Ovarian Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), TNBC - Triple-Negative Breast Cancer
- Interventions
- YF550
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The occurrence and frequency of Treatment-emergent adverse events (TEAEs) | From first dose through 30 days after the last dose of study treatment(up to approximately 36 months) | phase 1a |
| Primary | The occurrence and frequency of Dose-limiting toxicities (DLTs) DLTs during the study | first cycle (each cycle is 21 days) | phase 1a |
| Primary | Objective remission rate (ORR) assessed by the investigator according to RECIST v1.1 | Every 6 weeks (±7 days) during the first 48 weeks from Cycle 1 Day 1 (C1D1,each cycle is 21 days), and every 9 weeks (±7 days) thereafter (up to approximately 36 months) | Phase 1b |
| Secondary | Objective Response Rate (ORR) per RECIST v1.1 | Every 6 weeks (±7 days) during the first 48 weeks from Cycle 1 Day 1 (C1D1,each cycle is 21 days), and every 9 weeks (±7 days) thereafter (up to approximately 36 months) | Phase 1a |
| Secondary | Disease Control Rate (DCR) per RECIST v1.1 | Every 6 weeks (±7 days) during the first 48 weeks from Cycle 1 Day 1 (C1D1,each cycle is 21 days), and every 9 weeks (±7 days) thereafter (up to approximately 36 months) | Phase 1a and Phase 1b |
| Secondary | Progression-Free Survival (PFS) per RECIST v1.1 | Every 6 weeks (±7 days) during the first 48 weeks from Cycle 1 Day 1 (C1D1,each cycle is 21 days), and every 9 weeks (±7 days) thereafter (up to approximately 36 months) | Phase 1a and Phase 1b |
| Secondary | Duration of Response (DOR) per RECIST v1.1 | Every 6 weeks (±7 days) during the first 48 weeks from Cycle 1 Day 1 (C1D1,each cycle is 21 days), and every 9 weeks (±7 days) thereafter (up to approximately 36 months) | Phase 1a and Phase 1b |
| Secondary | Overall Survival (OS) | approximately 36 months | Duration from the date of initial treatment to the date of death due to any cause |
| Secondary | Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Measurable Time Point (AUC₀-t) | every 2 weeks in Cycle 1 (each cycle is 21 days) and every 4 cycles until end of treatment (up to approximately 36 months) | Area under the plasma concentration-time curve of YF550 from time zero to the last measurable time point. |
| Secondary | Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC₀-∞) | every 2 weeks in Cycle 1 (each cycle is 21 days) and every 4 cycles until end of treatment (up to approximately 36 months) | Area under the plasma concentration-time curve of YF550 from time zero extrapolated to infinity. |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07894874
GET https://conductscience.org/api/trials/v1/NCT07894874/registered